Cochrane · systematic review · CD007038
Factor Xa inhibitors for acute coronary syndromes
Brito, V, Ciapponi, A, Kwong, J · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 11.1%High 8 · 88.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Factor Xa inhibitors compared to Anticoagulants in ACS for acute coronary syndromes
Population: Anticoagulants in ACS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All causes of mortality at 30 days Factor Xa inhibitors vs Anticoagulants | RR 0.9 [0.8, 1.01] | 4 studies · 27976 participants | High |
All causes of mortality at 30 days ‐ UFH Factor Xa inhibitors vs Anticoagulants | RR 0.98 [0.82, 1.18] | 2 studies · 6760 participants | High |
All causes of mortality at 30 days ‐ Enoxaparin Factor Xa inhibitors vs Anticoagulants | RR 0.85 [0.73, 0.98] | 2 studies · 21216 participants | High |
Major bleeding at 30 days Factor Xa inhibitors vs Anticoagulants | RR 1.01 [0.98, 1.04] | 2 studies · 20404 participants | High |
Major bleeding at 30 days ‐ UFH Factor Xa inhibitors vs Anticoagulants | RR 0.98 [0.92, 1.04] | 1 study · 326 participants | High |
Major bleeding at 30 days ‐ Enoxaparin Factor Xa inhibitors vs Anticoagulants | RR 1.02 [1.01, 1.02] | 1 study · 20078 participants | High |
Minor bleeding at 30 days Factor Xa inhibitors vs Anticoagulants | RR 0.7 [0.14, 3.39] | 2 studies · 20404 participants | High |
Minor bleeding at 30 days ‐ UFH Factor Xa inhibitors vs Anticoagulants | RR 1.76 [0.52, 5.94] | 1 study · 326 participants | Moderate |
Minor bleeding at 30 days ‐ Enoxaparin Factor Xa inhibitors vs Anticoagulants | RR 0.34 [0.28, 0.43] | 1 study · 20078 participants | High |